

---

<b><i>Company Location</i></b>	<b><i>Contact Numbers</i></b>	<b><i>Contact 1</i></b>	<b><i>Contact 2</i></b>
8125 North Hayden Road Scottsdale, AZ 85258	Tel: (602) 808-8800 Fax: (602) 808-0822	Kara Stancell <b>Title:</b> Investor Relations <a href="mailto:kstancell@medicis.com">kstancell@medicis.com</a> (602) 808-3869	Research and Development <a href="mailto:rd@medicis.com">rd@medicis.com</a>

---

## **Overview**

Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatologic, pediatric and podiatric conditions. Medicis offers a broad range of prescription productions in a number of therapeutic categories, including acne, asthma, eczema, fungal infections, hyperpigmentation, photoaging, psoriasis, rosacea, seborrheic dermatitis, and skin and skin-structure infections.

The Company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.

New product developments, internal growth, acquisitions and strategic collaborations have driven the success and expansion of the Company. Careful execution of this strategy has yielded a compounded annual growth rate of nearly 40% over the past five years, and has provided uncommon stability in operating results.

With a balanced business in North America and an extraordinary track record of revenue, operating income growth and impressive gross profit margins, Medicis is driven to continue its success and assure long-term shareholder value.

With a keen eye for new opportunities, combined with its strong financial condition, Medicis seeks to expand its already successful business into new markets. Medicis has completed several company, product and technology acquisitions, and expects to continue its vigorous business development program as an important element of its four-part growth strategy.

Medicis has historically been a prolific source of new dermatological products, introducing 21 new products since 1991. The Company plans to continue launching at least one new product from its rich research and development pipeline each fiscal year. Medicis is dedicated to providing unparalleled service, support and innovation to its expanding universe of medical specialties served.

We are committed to continued growth and are interested in learning about prospective opportunities in the specialty pharmaceutical market.